Please assess the completion status of the following clinical trial:

Trial Title: Pyronaridine Artesunate (3:1) in Children and Adults With Acute Plasmodium Vivax Malaria

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female patients between the age of 3 and 60 years, inclusive.~2. Body weight between 20 kg and 90 kg with no clinical evidence of severe malnutrition.~3. Presence of acute uncomplicated P. vivax mono-infection confirmed by:~   * Fever, as defined by axillary/tympanic temperature ≥37.5°C or oral/rectal temperature ≥38°C, or history of fever in the previous 24 hours (history of fever must be documented) and,~  * Positive microscopy of P. vivax with parasite density ≥250/ mcL of blood (including at least 50% of asexual parasites).~4. Written informed consent, in accordance with local practice, provided by patient and/or parent/guardian/spouse. If the patient is unable to write, witnessed consent is permitted according to local ethical considerations.~5. Ability to swallow oral medication.~6. Ability and willingness to participate based on information given to patient or parent or guardian and access to health facility.~Exclusion Criteria:~1. Presence of a mixed Plasmodium infection.~2. Presence of other clinical condition requiring hospitalization.~3. Presence of significant anaemia, as defined by Hb \<8 g/dL.~4. Known history or evidence of clinically significant disorders such as cardiovascular (including arrhythmia, QTc interval ≥450 msec), respiratory (including active tuberculosis), hepatic, renal, gastrointestinal, immunological (including active HIV-AIDS), neurological (including auditory), endocrine, infectious, malignancy, psychiatric or other abnormality (including recent head trauma).~5. Known history of hypersensitivity, allergic or adverse reactions to pyronaridine, chloroquine or artesunate or other artemisinins.~6. Known history of hypersensitivity, allergic or adverse reactions to chloroquine, primaquine and related agents.~7. Known active Hepatitis A IgM (HAV-IgM), Hepatitis B surface antigen (HBsAg) or Hepatitis C antibody (HCV Ab).~8. Known seropositive HIV antibody.~9. Have received any antimalarial treatment in the preceding 2 weeks, as determined by history and, whenever feasible, by screening test.~10. Have received antibacterial with known antimalarial activity in the preceding 2 weeks.~11. Have received any investigational drug within the past 4 weeks.~12. Liver function tests (AST/ALT levels) \>2.5 times the upper limit of normal range.~13. Known significant renal impairment as indicated by serum creatinine levels of \>1.4 mg/dL.~14. Female patients of child-bearing potential must be neither pregnant (as demonstrated by a negative pregnancy test) nor lactating, and must be willing to take measures to not become pregnant during the study period.~15. Previous participation in the present clinical trial with PA.

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- pyronaridine artesunate (Type: EXPERIMENTAL): The tablet strength is 180:60 mg oral PA plus chloroquine-placebo. Depending on their body weight, patients receive 1 to 4 tablets once a day, for 3 days. The actual dose-level range covered by this regimen is 7.2: 2.4 mg/kg to 13.8:4.6 mg/kg pyronaridine artesunate.
- chloroquine (Type: ACTIVE_COMPARATOR): The tablet strength is 155 mg oral chloroquine plus PA-placebo.~Patients receive:~For adults: 620 mg (i.e. 4 tablets) on Days 0 and 1 and 310 mg (i.e. 2 tablets) on Day 2. For children: 10 mg/kg on Days 0 and 1 and 5 mg/kg on Day 2.

Based on this trial design, predict the completion outcome and termination type (if applicable).